Business Wire

OpenLink Launches the First Comprehensive Trading, Treasury and Risk Cloud Platform


OpenLink, the global leader in trading, treasury and risk management solutions for the energy, commodities, corporate and financial services industries, today announced the launch of OpenLink Cloud – the world’s first and most comprehensive enterprise Cloud platform for trading, treasury and risk management.

OpenLink Cloud is designed to transform trading, treasury and risk departments, combining the best of OpenLink’s flagship products with an extensible and transparent platform for unprecedented agility and innovation. Delivering the highest standards of security for highly regulated, data-intensive organizations, OpenLink Cloud combines the strength and security of the Microsoft Azure platform with best-of-breed OpenLink security and tools to ensure that our clients’ mission-critical systems and data are protected at all times.

Patrick Reames, Managing Partner of Commodity Technology Advisory the leading CTRM market analyst firm noted: “While Cloud deployment of commodity trading solutions in the low and mid-tiers of the market has increased in recent years, the investment by OpenLink in the OpenLink Cloud will undoubtedly accelerate this movement across all tiers of the market. The commitment by many of the world’s largest energy and commodity trading firms to adopt OpenLink’s enterprise-scale Cloud solutions is a pivotal development in terms of how these systems will be deployed going forward.”

Jack Large, Cash and Treasury Management Consultant and Analyst for CTMfile, said, “The wait is over. There is now enough power and security in the OpenLink Cloud to move mission critical systems to their Cloud platform, combined with OpenLink’s functional strength in cash and treasury management, extensive trading, commodities and risk management, could make this combination a game changer. Time will tell.”

Developed in collaboration with over 50 of OpenLink’s largest and most sophisticated energy and financial services clients, OpenLink Cloud has been rigorously tested by those who place the highest demands on the software. Supported by a robust set of custom tools and services, OpenLink Cloud is designed to help clients of all sizes get up and running quickly and to simplify management, monitoring and support of both production and non-production environments. Customers will have immediate access to almost limitless computing power with the introduction of OpenLink’s dynamic scaling capabilities, providing advanced data management and richer analytics that enable greater market understanding, speed and evidence-based decision-making.

John O’Malley, CEO of OpenLink, added: “If you think you knew OpenLink, take another look. We have made a significant investment in OpenLink Cloud in response to our clients’ feedback. They are looking to reduce costs, advance risk analytics and scale their operations to transform how they run their businesses. The response from clients and pent-up demand from prospects has been staggering. OpenLink Cloud enables us to deliver our market leading solutions faster and with attractive subscription pricing models.”

Scott Rompala, Head of the Cloud Solutions Group at OpenLink, said: “The real untapped benefit our clients are sharing is how this new flexibility and efficiency will allow them to reimagine their business, take advantage of intraday volatility in the markets, and provide accurate and real-time views of their risk and exposures to management and the board on demand.”

OpenLink Cloud facilitates calculations of P&L and VaR-type metrics more frequently and with broader data sets. These enhanced capabilities will enable departments to produce real-time analytics and improved hedging strategies, optimize capital movement and provide greater insight into profitability drivers, enhancing overall the information available for decision-making.

The OpenLink Cloud platform integrates an ecosystem of multiple tools and partners to provide a complete solution with comprehensive security, supported 24x7 by OpenLink Cloud experts. With new subscription-based pricing and dynamic scaling our clients can now better manage cost, risk and implement a platform for unrivalled innovation.

For further information please visit

Contact information

Aspectus for OpenLink
Ellie Bacon (UK) / Bar Cudkevich (US)
+44 20 7242 8867 / +1 646 202 9845
Michael Golding, +44 7766398912
Global Head of Public Relations

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on